TrialClinical pharmacokinetics2017

Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.

Dymphy R H Huntjens et al.PubMed ↗Publisher ↗

No numbers read from the abstract.